GSK Offered Positive Phase II Data for its mRNA Seasonal Influenza Vaccine Candidate for the Control of Influenza at the OPTIONS XII Conference

On September 2, 2026, GSK shared positive Phase II results for its experimental mRNA seasonal flu vaccine at the OPTIONS XIII Conference for the Control of Influenza. The vaccine is designed to target equally haemagglutinin and neuraminidase, giving it a broader biological focus than regular flu vaccines that mainly target haemagglutinin. The Phase II study showed the vaccine was safe and well tolerated meeting licensed standards.

This development is a central step in GSK’s mRNA vaccine program and could change the competitive edge in the next generation of seasonal flu prevention. After these results, GSK plans to start Phase III testing in September 2026. The study showed that the vaccine created stronger immune responses against the flu strains tested compared to standard-dose vaccines in younger adults and high-dose vaccines in older adults.

Impact on the Biopharmaceuticals Industry

The global biopharmaceuticals market size is calculated at USD 537.54 billion in 2025 and is predicted to increase from USD 616.02 billion in 2026 to approximately USD 1,983.73 billion by 2035, expanding at a CAGR of 13.95% from 2026 to 2035.

According to Precedence Research, the expanding demand for personalized medicine and surge in the biotechnology sector drive the move towards clinical trials. GSK’s progress could increase the competitive landscape in the pharmaceutical industry as companies look for well-cured seasonal flu vaccines. Moving an mRNA vaccine into Phase III gives GSK a chance to strengthen its place in a market led by traditional vaccine methods.

The dual-antigen approach might also encourage drug makers to explore broader immune targets instead of focusing on just one viral protein. For now, the results create momentum but do not guarantee commercial success. If Phase III shows clear health benefits, the program could affect research focus, investment choices, and future alliances in the biopharmaceutical industry.

Impact on the Vaccine Industry

The global vaccines market size was estimated at USD 91.97 billion in 2025 and is predicted to increase from USD 97.97 billion in 2026 to approximately USD 170.60 billion by 2035, expanding at a CAGR of 6.37% from 2026 to 2035.

According to Precedence Research, this development could speed up the move toward more advanced flu vaccine technologies. GSK's mRNA vaccine uses a different method by targeting both haemagglutinin and neuraminidase. Traditional flu vaccines are still important, but how well they work can change depending on the flu strains and the age of the patient.

This might improve the range of immune protection and boost the response against seasonal flu. Success in late-stage testing would probably lead to substantial investment in mRNA vaccine production, picking the right targets, and quick seasonal updates. Additionally, it could push established vaccine makers to improve their own technologies to stay competitive.

Impact on the mRNA Vaccines and Therapeutics Industry

The global mRNA vaccines and therapeutics market size was accounted for USD 116.88 billion in 2025 and is expected to reach around USD 297.84 billion by 2035, expanding at a solid CAGR of 9.81% from 2026 to 2035.

According to Precedence Research, the rising application of mRNA-driven therapies for genetics and immunotherapy. This strategy of GSK’s results offers another main proof point for mRNA technology as developers move beyond COVID-19 vaccines. Positive Phase III results could encourage R&D efforts into mRNA vaccines for other lung diseases.

GSK’s choice to target haemagglutinin and neuraminidase also shows how mRNA technology can support more complex vaccine designs. Seasonal flu is an indispensable test because it needs regular vaccine updates, inclusive strain coverage, and robust results across different age groups. A successful mRNA flu vaccine could show that this technology has bigger commercial potential in well-known infectious disease infrastructure.

Expert Opinion

According to expert opinion, the Phase II results for GSK are encouraging, but their significance has to be assessed in view of what happens in the next stage of the trial. This initiative-support candidate vaccine, which aims to target haemagglutinin and neuraminidase, addresses two important characteristics of the virus in mRNA therapeutics, biopharmaceuticals, and the vaccine industry. In current research, a requirement for a strong immune response, where the vaccine will provide improved real-world protection against influenza.

Within the industry, GSK hopes to assume a potentially major role in the development of mRNA influenza infrastructure, and this transformation into Phase III is therefore the most significant thing ahead. This method might possibly result in an improvement in the quality and the degree of protection, even though the true value of it will have to be decided upon the basis of clinical evidence. An expert said if both efficacy and tolerability keep on positive, the programme could increase assurance in mRNA technology for use in regular seasonal vaccination.